Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes
Shots:
- The NMPA has accepted 2nd NDA of mazdutide (a glucagon-like peptide-1 receptor & glucagon receptor dual agonist) as a treatment of type 2 diabetes
- The NDA was supported by P-III (DREAMS-1 & DREAMS-2) trials assessing the safety & efficacy of mazdutide alone and in addition to oral antidiabetic drugs (OADs), respectively, among T2D Chinese patients
- In the trials, mazdutide was superior to PBO or mazdutide (1.5mg) in controlling glycemia, weight loss as well as improved cardiovascular & renal indicators; safety profile was consistent with the prior studies. Data will be highlighted at conferences or in peer-reviewed journals
Ref: Innovent | Image: Innovent
Related News:- Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
